High dexamethasone concentration prevents stimulatory effects of TNF-α and LPS on IL-6 secretion from the precursors of human muscle regeneration
Authors:
- Tomaz MarsTMTomaz Mars
- Marko JevsekMJMarko Jevsek
- Matej PodbregarMPMatej Podbregar
- Zoran GrubicZGZoran Grubic
- 1 December 2006
- journal article
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 291 (6) , R1651-R1656
Abstract
A frequent finding in patients surviving critical illness myopathy is chronic muscle dysfunction. Its pathogenesis is mostly unknown; one explanation could be that muscle regeneration, which normally follows myopathy, is insufficient in these patients because of a high glucocorticoid level in their blood. Glucocorticoids can prevent stimulatory effects of proinflammatory factors on the interleukin (IL)-6 secretion, diminishing in this way the autocrine and paracrine IL-6 actions known to stimulate proliferation at the earliest, myoblast stage of muscle formation. To test this hypothesis, we compared the effects of major proinflammatory agents [tumor necrosis factor (TNF)-α and endotoxin lipopolysaccharide (LPS)] on the IL-6 secretion from the muscle precursors and then studied the influence of dexamethasone (Dex) on these effects. Mononuclear myoblasts, which still proliferate, were compared with myotubes in which this capacity is already lost. For correct interpretation of results, cultures were examined for putative apoptosis and necrosis. We found that constitutive secretion of IL-6 did not differ significantly between myoblasts and myotubes; however, the TNF-α- and LPS-stimulated IL-6 release was more pronounced ( P < 0.001) in myoblasts. Dex, applied at the 0.1–100 nM concentration range, prevented constitutive and TNF-α- and LPS-stimulated IL-6 release at both developmental stages but only at high concentration ( P < 0.01). Although there are still missing links to it, our results support the concept that high concentrations of glucocorticoids, met in critically ill patients, prevent TNF-α- and LPS-stimulated IL-6 secretion. This results in reduced IL-6-mediated myoblast proliferation, leading to the reduced final mass of the regenerated muscle.Keywords
This publication has 35 references indexed in Scilit:
- Reduced glucocorticoid sensitivity of monocyte interleukin-6 release in male employees with high plasma levels of tumor necrosis factor-αLife Sciences, 2004
- Toll-like receptors and TLR-mediated signaling: more questions than answersAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- p38 MAPK-induced Nuclear Factor-κB Activity Is Required for Skeletal Muscle Differentiation: Role of Interleukin-6Molecular Biology of the Cell, 2004
- Toxoplasma gondii infection can regulate the expression of tumour necorsis factor‐α receptors on human cell in vitroParasite Immunology, 2002
- Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stressBiochemical Journal, 2002
- Differentiation of glial cells and motor neurons during the formation of neuromuscular junctions in cocultures of rat spinal cord explant and human muscleJournal of Comparative Neurology, 2001
- Dexamethasone Inhibits Insulin-Like Growth Factor Signaling and Potentiates Myoblast ApoptosisEndocrinology, 2000
- Two tumour necrosis factor receptors: structure and functionTrends in Cell Biology, 1995
- Myoblast fusion and innervation with rat motor nerve alter distribution of acetylcholinesterase and its mRNA in cultures of human muscleNeuron, 1995
- De novo neuromuscular junction formation on human muscle fibres cultured in monolayer and innervated by foetal rat spinal cord: Ultrastructural and ultrastructural-cytochemical studiesJournal of Neurocytology, 1987